L20 ANSWER 37 OF 47 USPATFULL
ACCESSION NUMBER: 91:52474 USPATFULL
TITLE: Threshold ligand-receptor assay
INVENTOR(S): Buechler, Kenneth F., Santee, CA, United States
Valkirs, Gunars E., Escondido, CA, United States
Anderson, Richard R., Encinitas, CA, United States
PATENT ASSIGNEE(S): Biosite Diagnostics, Inc., San Diego, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5028535		19910702	<--
APPLICATION INFO.:	US 1989-295568		19890110	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Warden, Robert J.
ASSISTANT EXAMINER: Spiegel, Carol A.
LEGAL REPRESENTATIVE: Consalvi, Mary S.
NUMBER OF CLAIMS: 70
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 2055
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 5028535 19910702 <--
SUMM Reaction Phase - The phase normally containing the ligand analogue **conjugate**, e.g., **hapten**-enzyme **conjugate**, and **ligand** receptor, e.g., an antibody.
DETD . . . drugs. Subsequent to the elicitation of an immune response, the
mice are sacrificed and the spleen cells are fused with **myeloma** cells to produce antibody secreting hybridoma cell lines. Further characterization of the antibodies derived from the cell lines is achieved. . .

L2 ANSWER 21 OF 24 SCISEARCH COPYRIGHT 2003 ISI (R)
ACCESSION NUMBER: 92:103074 SCISEARCH
THE GENUINE ARTICLE: HD549
TITLE: CARRIER SEQUENCE SELECTION - ONE KEY TO SUCCESSFUL VACCINES

AUTHOR: ETLINGER H M (Reprint)
CORPORATE SOURCE: F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES NEW TECHNOL, CH-4002 BASEL, SWITZERLAND (Reprint)
COUNTRY OF AUTHOR: SWITZERLAND

SOURCE: IMMUNOLOGY TODAY, (**FEB 1992**) Vol. 13, No. 2, pp. 52-55.
ISSN: 0167-4919.
DOCUMENT TYPE: Editorial; Journal
FILE SEGMENT: LIFE
LANGUAGE: ENGLISH
REFERENCE COUNT: 53

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB The trend towards epitopic vaccines has brought with it the problem of ensuring carrier function, a role previously filled by carrier sequences of the attenuated organism. Here, Howard Etlinger proposes the use of carrier epitopes, derived from vaccines already in use and selected for their ability to activate only helper T-cell responses, in the administration of B-cell-specific epitopic vaccines.